An interventional study of Placebo Tiotropium inhalation powder type A and Placebo Spiriva capsule in Healthy Volunteer and COPD, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Estonia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-27.
Sponsored by Orion Corporation, Orion Pharma · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Pulmonary Disease, Chronic Obstructive with a site in Estonia — 1 open to participants now, 1 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Estonia.
Among the 42 studies in Pulmonary Disease, Chronic Obstructive with a site in Estonia, this one is the 38th largest by enrollment, is one of 3 that started in 2019, is one of 4 with no phase, and was the 37th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 42 studies in Pulmonary Disease, Chronic Obstructive with a site in Estonia is open now. Recruiting first, the newest first:
Sanofi · Sites in Estonia, United States, Argentina and 22 more countries
Ages 40–80
A study can be open while its sites in Estonia have not opened yet or have stopped. Only those recruiting at a site in Estonia →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 730 across the 42 interventional studies. Of the 40 that completed or were terminated, 29 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 42 have an industry lead sponsor. The 10 most frequent:
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Orion Corporation, Orion Pharma has 5 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 42 studies in Pulmonary Disease, Chronic Obstructive with a site in Estonia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will characterise inspiratory flow parameters across placebo dry powder inhaler Easyhaler (2 inhaler versions) and placebo Spiriva inhalation powder capsule inhaled via HandiHaler in patients with chronic obstructive pulmonary disease (COPD) and in healthy volunteers.
Substudy: Easyhaler® and HandiHaler® Usability study in patients with COPD; to assess patients acceptability, preference, correct use and ability to learn to use Easyhaler and HandiHaler (with capsules) and to compare PIF rate via In-Check Dial meter with the PIF rate via spirometer in the main study.
This is an open, randomised, multicentre, crossover study with Easyhaler and HandiHaler inhalers. The primary objective is to characterise inspiratory flow parameters across placebo dry powder inhaler Easyhaler (2 inhaler versions) and placebo Spiriva inhalation powder capsule inhaled via HandiHaler in patients with chronic obstructive pulmonary disease (COPD) and in healthy volunteers. The secondary objective is to calculate correlation of peak inspiratory flow (PIF) rate with regards to anthropometric and lung function parameters.
Substudy: This is an open, randomised, multicentre, crossover study with Easyhaler and HandiHaler inhalers.There will be 1 study visit per subject, usually this visit is done at the same visit with the main study.
Inclusion Criteria for subjects with :
Inclusion Criteria for healthy volunteers:
Exclusion Criteria for subjects with COPD:
Exclusion Criteria for healthy volunteers:
Substudy:
Patients with documented diagnosis of COPD aged 18 year or older participating the main study will be enrolled in this substudy. Written informed consent (IC) will be obtained.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Tiotropium Easyhaler, type A
Drug: Placebo Tiotropium inhalation powder type A
Placebo Tiotropium Easyhaler, type B
Drug: Placebo Tiotropium inhalation powder type B
Placebo Spiriva, hard capsule inhaled via modified HandiHaler device
Drug: Placebo Spiriva capsule
The substudy subjects will demonstrate the use of the inhaler.
Device: Substudy Placebo Tiotropium Easyhaler
The substudy subjects will demonstrate the use of the inhaler.
Device: Substudy Placebo Spiriva® via HandiHaler
Placebo inhalation from inhaler A
Placebo inhalation from HandiHaler
Placebo inhalation from inhaler B
Substudy placebo inhalation
Substudy placebo inhalation
The primary variable will be the PIF rate through the Easyhaler and HandiHaler inhalers.
After practising, 3 inspiratory flow curves will be recorded and the inhalation with the highest PIF rate analysed.
Time frame: 1 day
Inspiratory volume through the Easyhaler and HandiHaler inhalers
Highest inspiratory volume recorded and analysed from the same inhalation as the PIF rate.
Time frame: 1 day
Correct use of Easyhaler and HandiHaler tabulated by frequencies and percents based on the inhaler specific questionnaire, assessed by the site staff.
Substudy outcome
Time frame: 1 day
Patient's acceptability of inhalers, assessed by the study specific questionnaire
Substudy outcome
Time frame: 1 day
Patient's preference of inhalers assessed by study specific questionnaire
Substudy outcome
Time frame: 1 day
Patient's ability to learn the use of the inhalers, assessed by the study specific questionnaire.
Substudy outcome
Time frame: 1 day
Peak inspiratory flow measurement via In-Check Dial
Substudy outcome
Time frame: 1 day
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2019 to primary completion in Jan 2020, 2 months.
Of 88 industry-sponsored interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 2 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Orion Corporation, Orion Pharma →